Literature DB >> 32339091

Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan.

Shu-Chen Kuo, Shu-Man Shih, Li-Hsin Chien, Chao A Hsiung.   

Abstract

Taiwan has strictly followed infection control measures to prevent spread of coronavirus disease. Meanwhile, nationwide surveillance data revealed drastic decreases in influenza diagnoses in outpatient departments, positivity rates of clinical specimens, and confirmed severe cases during the first 12 weeks of 2020 compared with the same period of 2019.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Taiwan; coronavirus disease; infection control measures; influenza; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Year:  2020        PMID: 32339091      PMCID: PMC7392415          DOI: 10.3201/eid2608.201192

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


After the 2003 severe acute respiratory syndrome coronavirus epidemic, the government and public of Taiwan have been vigilant about the threat of emerging infectious diseases. The government of Taiwan took swift action to prevent coronavirus disease (COVID-19) importation and outbreaks (). The public has adhered well to control measures that included avoiding gatherings, maintaining social distance, mask wearing, hand and respiratory hygiene, temperature monitoring, and quarantine of high-risk and sick persons (Figure, panel A). Although the success of these measures for limiting COVID-19 transmission remains to be determined, nationwide surveillance has shown the rapid decline of influenza activity during the first 12 weeks of 2020 (through March 21) in Taiwan.
Figure

Influenza and varicella activity in Taiwan during the first 12 weeks of 2020 compared with the corresponding time period in 2019. A) Number of outpatient department visits in which the diagnosis of influenza-like illness (ILI) was made (bars) and the rate of ILI diagnoses per 1,000 visits (lines). Notable dates during the coronavirus disease pandemic are marked along the baseline. B) Number of specimens positive for influenza. C) Number of strains of influenza identified in commissioned laboratories (bars) and the number of positive specimens/total specimens positivity rate (lines). D) Number of laboratory-confirmed influenza cases with severe complications. E) Number of outpatient department visits in which the diagnosis of varicella infection was made (bars) and the rate of varicella diagnoses per 1,000 visits (lines). The 9-day Lunar New Year holiday in week 6 of 2019, when most healthcare service was unavailable, resulted in extreme data, which we excluded from the analysis.

Influenza and varicella activity in Taiwan during the first 12 weeks of 2020 compared with the corresponding time period in 2019. A) Number of outpatient department visits in which the diagnosis of influenza-like illness (ILI) was made (bars) and the rate of ILI diagnoses per 1,000 visits (lines). Notable dates during the coronavirus disease pandemic are marked along the baseline. B) Number of specimens positive for influenza. C) Number of strains of influenza identified in commissioned laboratories (bars) and the number of positive specimens/total specimens positivity rate (lines). D) Number of laboratory-confirmed influenza cases with severe complications. E) Number of outpatient department visits in which the diagnosis of varicella infection was made (bars) and the rate of varicella diagnoses per 1,000 visits (lines). The 9-day Lunar New Year holiday in week 6 of 2019, when most healthcare service was unavailable, resulted in extreme data, which we excluded from the analysis. The Taiwan National Infectious Disease Statistics System (), maintained by the Taiwan Centers for Disease Control, is an open data portal that provides nationwide surveillance data on infectious diseases (https://nidss.cdc.gov.tw). For this study, we analyzed data from outpatient department visits for selected syndromes, clinical specimen testing, isolated respiratory pathogens, and confirmed severe cases (Appendix). The institutional review board of the National Health Research Institutes approved this study (EC1051207-R4). We compared changes across the first 12 weeks of 2020 with data from the same period of 2019 using simple linear regression. (The 9-day Lunar New Year holiday in week 6 of 2019, when most healthcare service was unavailable, resulted in extreme data; therefore, we excluded these data from analysis.) We saw fewer outpatient department visits for influenza-like illness (ILI) and ILI diagnoses per 1,000 visits during weeks 8–12 of 2020 compared with 2019 (Figure, panel A). The changes (slopes of the regression lines) of ILI visits (−8,061 vs. −590 per week; p<0.05) differed between 2020 and 2019, as did the changes in ILI diagnoses per 1,000 visits (−1.5 vs. −0.2 per week; p<0.05). The slopes of the regression lines for positive samples (−360 vs. −77 per week; p<0.05) also differed between 2020 and 2019 (Figure, panel B). Both the number of influenza strains isolated from clinical specimens in commissioned laboratories and the positivity rate dropped drastically in 2020; the trends were different from 2019 (p<0.05 for both) (Figure, panel C). The number of cases of confirmed influenza with severe complications decreased from 99 to 1 in 2020, compared with a decrease from 44 to 22 in 2019 (p<0.05) (Figure, panel D). In contrast, the number of outpatient department visits for varicella and the number of varicella diagnoses per 1,000 visits remained similar in 2020 and 2019 (p = 0.660 for outpatient department visits and p = 0.157 for varicella diagnosis) (Figure, panel E). The functional healthcare and surveillance systems in Taiwan, the government’s efforts to identify causes of ILI during the COVID-19 pandemic, and sufficient laboratory capacity ensure appropriate influenza testing and reporting of results. Healthcare avoidance during COVID-19 pandemic may be an important confounder for the results we reported. However, because of awareness of the similarities in symptoms between COVID-19 and influenza and the low number of COVID-19 patients in Taiwan (<200 cases as of March 21, 2020), patients with ILI would not avoid seeking medical help for a diagnosis. Healthcare avoidance also did not explain the lower number of severe influenza cases observed in 2020 (Figure, panel D). Therefore, we believe that the decreasing influenza activity in Taiwan in 2020 is the result of strict control measures that were established in response to COVID-19.

Appendix

Additional information about collateral benefits of COVID-19 control measures on influenza activity in Taiwan.
  2 in total

1.  Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing.

Authors:  C Jason Wang; Chun Y Ng; Robert H Brook
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

2.  Real-Time Surveillance of Infectious Diseases: Taiwan's Experience.

Authors:  Shu-Wan Jian; Chiu-Mei Chen; Cheng-Yi Lee; Ding-Ping Liu
Journal:  Health Secur       Date:  2017 Mar/Apr
  2 in total
  49 in total

1.  Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020-2022).

Authors:  José María Díez; Daniel Casals; Carolina Romero; Rodrigo Gajardo
Journal:  Open Forum Infect Dis       Date:  2022-04-28       Impact factor: 4.423

2.  Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada.

Authors:  Philippe Lagacé-Wiens; Claire Sevenhuysen; Liza Lee; Andrea Nwosu; Tiffany Smith
Journal:  Can Commun Dis Rep       Date:  2021-03-31

3.  The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study.

Authors:  Helen E Groves; Pierre-Philippe Piché-Renaud; Adriana Peci; Daniel S Farrar; Steven Buckrell; Christina Bancej; Claire Sevenhuysen; Aaron Campigotto; Jonathan B Gubbay; Shaun K Morris
Journal:  Lancet Reg Health Am       Date:  2021-07-17

4.  Increase in the incidence of acute inflammatory reactions to injectable fillers during COVID-19 era.

Authors:  Kiyoko Kato; Eiko Inoue; Sakae Tanaka; Hiroshi Kawamoto
Journal:  J Cosmet Dermatol       Date:  2022-03-12       Impact factor: 2.189

5.  Social Distancing Measures: Evidence of Interruption of Seasonal Influenza Activity and Early Lessons of the SARS-CoV-2 Pandemic.

Authors:  Andrew D Wiese; Jordan Everson; Carlos G Grijalva
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

6.  Influenza activity during the outbreak of coronavirus disease 2019 in Chinese mainland.

Authors:  Mi Liu; Lizong Deng; Dayan Wang; Taijiao Jiang
Journal:  Biosaf Health       Date:  2020-09-02

7.  Changes in the incidence of seasonal influenza in response to COVID-19 social distancing measures: an observational study based on Canada's national influenza surveillance system.

Authors:  Andrew Pierce; Margaret Haworth-Brockman; Diana Marin; Zulma V Rueda; Yoav Keynan
Journal:  Can J Public Health       Date:  2021-05-28

8.  Predictability of COVID-19-related morbidity and mortality based on model estimations to establish proactive protocols of countermeasures.

Authors:  Göran Svensson; Rocio Rodriguez; Carmen Padin
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

Review 9.  Effects of COVID-19 prevention procedures on other common infections: a systematic review.

Authors:  Omid Dadras; Seyed Ahmad Seyed Alinaghi; Amirali Karimi; Mehrzad MohsseniPour; Alireza Barzegary; Farzin Vahedi; Zahra Pashaei; Pegah Mirzapour; Amirata Fakhfouri; Ghazal Zargari; Solmaz Saeidi; Hengameh Mojdeganlou; Hajar Badri; Kowsar Qaderi; Farzane Behnezhad; Esmaeil Mehraeen
Journal:  Eur J Med Res       Date:  2021-07-03       Impact factor: 2.175

10.  The impact of COVID-19 pandemic on the health-seeking behaviour of an Asian population with acute respiratory infections in a densely populated community.

Authors:  Hwee Mian Jane Tan; Mui Suan Tan; Zi Ying Chang; Kee Tung Tan; Guan Liang Adrian Ee; Chee Chin David Ng; Ying Khee William Hwang; Yi Ling Eileen Koh; Yan Ping Sarah Low; Ngiap Chuan Tan
Journal:  BMC Public Health       Date:  2021-06-23       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.